India · Updated November 2026 · Revised Schedule M design basis

Pharma Plant Setup Cost Calculator

Estimate what a pharmaceutical manufacturing plant costs to build, expand or upgrade in India — dosage form by dosage form, at your own capacity, on a Revised Schedule M, WHO-GMP, EU-GMP or US-market-oriented design basis. You get a low, likely and high project cost, then the timeline, manpower, running cost and finance view that go with it.

Low · likely · high range 16 dosage-form packages Timeline, manpower, EMI Scenario comparison Printable report

Project Cost Estimator

Laafon project-rate basis · INR · indicative 2026
Step 1 of 6Project and site

What are you building, and where?

A new plant, a new block on an existing site and an upgrade of a running plant are three different projects with three different cost shapes. Pick the one that matches yours.

Project type

Loading
Loading
Excluding land makes the estimate comparable across states.
Auto-filled from state and site type. Overwrite with your actual quoted rate.
Used to derive minimum land area from built-up area.
Your plan inputs are saved in this browser as you go.

Estimated project cost

Select a dosage form

Indicative planning estimate at 2026 prices, excluding GST. Not a quotation, benchmark, or regulatory or financial advice. Actual costs vary with location, vendor, design, product, taxes and approvals.

Get a detailed project report and plant layout from Laafon

Unlocks instantly on this page · reviewed by our team

  • Month-by-month project timeline
  • Manpower by department and salary bill
  • Monthly running cost
  • EMI, break-even, ROI and payback
  • Suggested floor layout zones and areas
  • Licences and approvals checklist
  • Side-by-side scenario comparison
  • Printable report you can save as PDF
Send this project on WhatsApp

We use these details only to send your report and answer questions about it. Your plan inputs are kept in this browser so you can return to them; your name and contact details are not. Reset clears the plan.

Where the money goes

Each bar is a cost head at the likely estimate. The line-by-line detail is below the chart.

Cost breakdown — tap any line for detail

Same plant, four standards

Identical dosage forms and capacities, priced under each compliance grade, excluding land.

Lower-capital routes to the same market

How to read this estimate. Figures are built bottom-up from component rates — machinery per dosage form, HVAC and cleanroom finish per sq ft of classified area, utilities sized on connected load, and laboratory, validation and pre-operative allowances per compliance grade. Every rate is listed in the methodology section below. Equipment is priced at domestic Indian OEM levels, 2026, excluding GST, unless you choose a higher machinery level. The low and high figures are the planning band for the chosen standard and project type, not a guarantee of either. These are indicative planning figures, not a quotation. Actual costs move with vendor selection, imported versus domestic equipment, site conditions, statutory fees and procurement timing. Use this to size funding and compare configurations, then commission a Detailed Project Report before committing capital.

How much does it cost to set up a pharma plant in India?

On this model, a single tablet section at 5 lakh tablets per day, built to Revised Schedule M, comes to roughly ₹10 crore excluding land on about 10,500 sq ft built-up, including QC laboratory, utilities, contingency and working capital margin. A three-section WHO-GMP unit — tablets, capsules and liquid orals — lands near ₹23 crore. A sterile liquid-vial injectable facility at EU-GMP is closer to ₹27 crore. Land typically adds under 10 per cent. For export grades the standard moves the number more than capacity does: the same tablets-plus-capsules plant prices at about ₹14.6 crore under Schedule M and ₹24.4 crore under EU-GMP.

Which route actually fits you?

Two questions. The answer tells you whether to build, upgrade or buy — and what to do next.

1. What do you have today?

2. Which market are you supplying?

Choose an answer to both questions

Your route depends on what you already own and where the product is going. Pick one option in each row above.

Understanding the numbers

What actually drives pharma plant cost in India

Most published estimates fail because they treat compliance grade as a footnote. In practice it outweighs capacity, location and even dosage form.

Where Revised Schedule M stands, and what it means for a new build

Revised Schedule M was notified through G.S.R. 922(E) dated 28 December 2023[1]. G.S.R. 127(E), dated 11 February 2025, allowed eligible small and medium manufacturers with turnover below ₹250 crore to seek an extension until 31 December 2025 by submitting the required application and upgradation plan[2]. That window has closed, no further extension has been notified, and the rules are in the enforcement phase: in November 2025 the DCGI directed state and UT drug controllers to begin inspections immediately for units that had not sought an extension, with units holding extensions to be inspected from January 2026[9]. Confirm your own unit’s position with CDSCO and your State Licensing Authority.

For a new build the practical consequence is simpler than for an existing unit: Revised Schedule M is the Indian GMP text a new plant is designed and licensed against, so the domestic baseline in the calculator above assumes it. If you already operate a unit, choose “Upgrade an existing plant” in Step 01 for an order-of-magnitude retrofit allowance, and use the Revised Schedule M compliance dashboard to score readiness across the twelve areas inspectors look at. A retrofit figure from any calculator is only a placeholder until a gap assessment has been done on the actual plant.

Compliance standard is the dominant cost variable

The same plant — same dosage forms, same capacity, same state — costs roughly 60 to 100 per cent more when built to an EU-GMP or US-market-oriented basis than to Revised Schedule M. It is worth being precise about why, because the popular explanation, that export-grade machines cost many times more, overstates the equipment effect and understates everything around it.

What genuinely changes as you move from Revised Schedule M to WHO-GMP[3], then to EU-GMP[4] and a US-market-oriented design basis[6] is a stack of things that each carry capital cost: tighter cleanroom classification and therefore heavier HVAC and filtration; more instrumented and automated equipment with full material-of-construction documentation; electronic records and data integrity capability across every system that generates GMP data; a far larger qualification and validation programme; wider corridors and airlocks for segregation and personnel flow; and a QC laboratory carrying analytical instrumentation of a different order.

Sterile products carry an additional design layer. For sterile manufacture specifically, the EU GMP Annex 1 revision published on 25 August 2022 and in operation from 25 August 2023, with the lyophilisation provision at point 8.123 deferred to 25 August 2024, makes a documented contamination control strategy and barrier technology an explicit design expectation rather than a preference[5]. That applies to injectables, ophthalmics and other sterile dosage forms; it does not govern oral solids or liquid orals.

The calculator prices each of those effects separately rather than applying one blanket multiplier. Equipment carries a grade factor of 1.1 for WHO-GMP, 1.7 for EU-GMP and 2.0 for a US-oriented basis, reflecting a mix of export-grade domestic and imported machines with full documentation. Classified area grows by 5 to 25 per cent for segregation and airlocks. HVAC runs from about ₹1,300 per sq ft of classified area for a Schedule M oral solid block to ₹4,000 or more for sterile Grade B and C areas. Validation, laboratory and computerised-system allowances step up by grade. The full rate table is in the methodology section below. Treat the Schedule M and WHO-GMP figures as reasonably firm and the EU-GMP and US-oriented figures as indicative, with a wider band, because at that end the spread between two credible vendor lists is genuinely large.

One thing the US-oriented tier is not. Building to a US-market-oriented design basis is a design and capital decision only. It is not a certification, an accreditation, or any guarantee of USFDA approval — that depends on the marketing application, the outcome of facility inspection, and sustained compliance thereafter. The tier exists here so you can size the capital gap before deciding whether to pursue that route, not to imply the route is secured by spending the money.

Capacity matters less than most promoters expect

Doubling output does not double cost. The calculator scales machinery with the six-tenths rule used in process-plant cost estimation, so machinery rises about 50 per cent for a doubling, and classified area rises about 37 per cent. Because the QC laboratory, utility backbone and support buildings barely change, the whole project rises only about 25 to 30 per cent for a doubling of capacity — on this model, a 5 lakh tablets-per-day Schedule M unit moves from about ₹10.1 crore to ₹12.7 crore at 10 lakh per day.

Shifts work the other way. Capacity is entered as output per day, so ten lakh tablets a day on two shifts needs the same line as five lakh on one — the capital stays near ₹10.1 crore and the extra cost moves into production manpower and power. For a plant that will sell on thin conversion margins, that is usually the difference between a project that pays and one that does not.

The practical implication: if you are choosing between 5 lakh and 10 lakh tablets per day, the larger line is almost always better on cost per unit — provided the market absorbs the output. If it does not, the cheaper route to volume is usually someone else’s line, which is what third-party manufacturing exists for.

Dosage-form packages, not machine lists

Each dosage form carries three linked costs: machinery, its classified area, and the HVAC that serves that area. A tablet section at 5 lakh per day needs about 7,000 sq ft classified; capsules at the same output about 4,000; liquid orals around 7,000; dry syrup 3,000; ointments and creams 2,500; and sterile injectables about 5,000 sq ft with a far heavier machinery and HVAC load. Beta-lactam tablet sections match non-beta on machinery but carry 30 per cent more HVAC cost for dedicated air handling and exhaust filtration, because segregation of penicillins and cephalosporins is not negotiable under any of these standards.

Eight further packages cover soft gelatin capsules, external liquids, ophthalmic drops, large volume parenterals, a cephalosporin block, a hormone and cytotoxic containment block, nutraceuticals and Ayurvedic products. Their rates rest on fewer reference projects than the core eight, so each one widens the planning band by five percentage points. The package table in the methodology section lists every rate so you can test them against your own quotations.

Land is smaller than most promoters assume

Greenfield land requiring industrial conversion runs roughly ₹150 to ₹400 per sq ft across the main pharma states — Himachal Pradesh (Baddi, Solan, Una) and Uttarakhand (Haridwar, Roorkee) around ₹300, Gujarat lower, Haryana higher. Change of Land Use charges add roughly 5 per cent of land value, though the rate and the process are state-specific and should be confirmed with the local authority before it goes into a funding plan. A developed plot in a notified industrial area, pharma park or SEZ costs more per sq ft but needs no conversion; the calculator applies a multiplier to the state rate for those, and you should overwrite it with the allotment price you are actually quoted. On most projects land ends up under 10 per cent of total cost — about 7 per cent for a tablets-plus-capsules unit in Himachal Pradesh on this model — which is why optimising location for vendor access, effluent infrastructure and skilled manpower usually beats optimising for cheap land.

Worked examples

Calculated on the same model this page runs, at default settings and excluding land so they stay comparable:

ConfigurationStandardBuilt-upCost excl. land
Tablets, non-beta — 5 lakh per day, Himachal PradeshRevised Schedule M~10,500 sq ft₹10.1 Cr
Tablets, capsules and liquid orals — reference capacities, UttarakhandWHO-GMP~25,500 sq ft₹23.3 Cr
Injectables, liquid vial — 1 lakh vials per day, HaryanaEU-GMP~10,000 sq ft₹26.6 Cr

Scroll the table sideways on a phone

And the comparison that matters most — one plant, tablets plus capsules in Himachal Pradesh excluding land, across all four grades:

StandardProject costvs Schedule MTypical market
Revised Schedule M₹14.6 CrbaselineDomestic India
WHO-GMP₹16.2 Cr+11%Africa, LatAm, CIS tenders
EU-GMP₹24.4 Cr+68%European regulated markets
US-market-oriented design basis₹28.1 Cr+93%United States

Scroll the table sideways on a phone

The step from Schedule M to WHO-GMP is modest — largely HVAC specification, stability capacity and cleanroom finish, since the underlying GMP principles are closely aligned. The step to EU-GMP or a US-market-oriented basis is a different order of investment, and should be underwritten by a committed export order book rather than optimism. Those two rows carry a wider uncertainty band than the first two, and the calculator reflects that in its low and high figures.

Timeline, manpower and running cost

The detailed report adds three things a capital figure alone cannot tell you. The timeline runs seven overlapping phases from land and approvals to commercial production. For the single tablet section above, with land still to be bought, the model gives about 18 months; sterile and export-grade plants run longer because design, equipment delivery and qualification each take more time. Statutory approvals do not run to a fixed clock, so the licensing phase is the one most likely to move.

Manpower is built from a production crew per dosage form per shift, plus QA, QC, engineering, stores and administration that grow with the number of dosage forms and the compliance grade. The same tablet section comes to about 43 people on one shift. Monthly running cost adds power on the connected load, maintenance, consumables and overheads to that salary bill. It deliberately excludes raw and packing materials, which sit inside the margin you enter in Step 06.

What the finance view assumes

The finance view is a first-pass screen, not a project appraisal. It takes your daily capacity, 300 working days a year and the utilisation you choose, multiplies by an average ex-factory value per unit, keeps the margin you enter after materials, and subtracts the monthly running cost. From that it reports EMI on a standard reducing-balance term loan, the utilisation at which the plant covers its running cost and its EMI, a simple pre-tax return on project cost, and payback. Depreciation, tax, interest during construction, ramp-up losses and GST on capital goods are outside it. The default selling values are deliberately conservative, set at today’s lowest average rates, so the screen errs on the cautious side until you enter your own.

Expect it to be blunt. A single-shift plant selling third-party manufacturing on contract margins will often cover its running cost but struggle to service its loan until utilisation is high — that is a real feature of the business, and it is the reason contract plants run two or three shifts. If your result looks poor, the report tells you what it would take to clear the EMI; change shifts, product value and margin before changing the plant, and compare the lower-capital routes the calculator lists: a loan licence, third-party manufacturing, a unit on rent, or an existing licensed plant.

Government schemes: what the yes or no flags mean

The calculator records whether you expect to qualify for support and carries that into your report. It does not deduct any subsidy from the estimate, for a simple reason: none of these can be assumed until eligibility and an open application window are confirmed for your unit.

The Revamped Pharmaceuticals Technology Upgradation Assistance Scheme was announced by the Department of Pharmaceuticals in March 2024 to support existing units upgrading to Revised Schedule M and WHO-GMP, with assistance on a reimbursement basis[10]. It is an upgrade scheme, so it bears on the upgrade project type rather than a greenfield build. Its clauses were modified again on 21 March 2026[11], and in August 2026 the government told Parliament that pending applications from Himachal Pradesh units were on hold under a temporary restriction, awaiting an expenditure committee decision[13]. Check with the Department whether applications are being processed before counting on it. The Production Linked Incentive schemes selected their participants through application rounds; the bulk-drug scheme has reopened only for specific products[12], and a new formulation plant should not budget for PLI unless a fresh round is notified. The central Industrial Development Scheme, 2017 for Himachal Pradesh and Uttarakhand closed to new units in March 2022, so hill-state sites should be costed on state industrial policy benefits alone, confirmed in writing.

What sits outside this estimate

The project cost covers capital cost to commissioning plus a working capital margin. The report adds indicative EMI, running cost, break-even and payback. Neither includes interest during construction in the project cost, GST on capital goods, API and excipient procurement, product development, dossier and registration costs, or tax. For funding structure, subsidies and payback expectations in more depth, read our companion guide to pharma manufacturing plant investment in India, which covers capex bands, the PLI scheme and financing. And if buying an existing licensed unit is faster than building one, compare plants listed for sale and rent before you commit to a greenfield timeline — each listing states how far its details have been checked.

Methodology and the rates this calculator uses

Each estimate is built bottom-up. Machinery is priced per dosage form at a reference capacity using domestic Indian OEM equipment at 2026 prices, excluding GST, and scaled to your per-shift capacity with a 0.6 exponent. HVAC and cleanroom finish are priced per sq ft of classified area; the building shell at ₹1,900 per sq ft for process blocks, ₹1,600 for the warehouse, ₹1,800 for utility and admin and ₹2,400 for the QC laboratory. Electrical infrastructure including transformer and DG set is sized on an estimated connected load at about ₹22,000 per kVA. Purified water, WFI, steam, compressed air, effluent treatment and fire-fighting are added as sized allowances. The resulting cost-head split was cross-checked against published capex breakdowns for Indian oral-dosage and injectable plants[7][8]. Expansion and upgrade projects apply reduction factors to the same heads, and carry a wider band because the real figure depends on what is already on site. Grade-dependent rates are below; they are generated from the same data the calculator runs on, so the two cannot drift apart.

RateSchedule MWHO-GMPEU-GMPUS-oriented

Scroll the table sideways on a phone

Dosage-form packages at reference capacity and Indian standard machinery, before the grade factor:

Dosage formReference capacity per shiftMachineryClassified areaCrew per shiftDefault value per unit

Scroll the table sideways on a phone

References

Common questions

Pharma plant cost, answered

Related on Laafon

Pharma plant investment in India

The narrative companion to this tool — capex bands, cost-component percentages, PLI and state subsidies, and how projects are financed.

Pharma plant setup consultant

GMP concept and layout design, room classification, flow and pressure cascade logic — the step that fixes most of the cost before civil work starts.

Schedule M compliance dashboard

A two-minute self-assessment scoring your existing unit across twelve inspection focus areas, with a status and applicability tracker.

Pharma plants for sale

Listings of licensed units, each marked with how far its details have been checked. Worth comparing against a greenfield build before you commit to the construction timeline.

Pharma units for rent

Licensed facilities available on rent, for promoters who want their own manufacturing address without construction capital.

Loan licence consulting

If you need product in the market before a plant can be commissioned, this is the interim route and what it involves.

Third-party manufacturing

Manufacturing on an existing approved line instead of building your own — usually the cheaper route to volume below a certain scale.

About the author

Darshan Singh, 23+ years in pharmaceutical quality control, quality assurance and drug regulatory affairs.

23+ years in pharmaceutical QA, QC and regulatory affairs

Get a detailed project report and plant layout from Laafon

GMP layout and room classification, equipment specification, a fundable cost basis and the licensing pathway for your chosen state.